MELBOURNE, Australia, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the Company has executed a partnership with US travel clinic leader Passport Health, for the sale of Travelan throughout its clinic network. The specific terms and conditions of this agreement will remain confidential.
Passport Health is the largest provider of travel medicine and immunisation services in North America. With 250+ travel clinic locations, a commitment to first class medical care, and rigorously trained medical staff, Passport Health has set a standard of excellence for patient care. Passport Health has leveraged its deep experience with travel medicine to service the vaccination, wellness, examination and records management needs of corporations, government agencies and other large organisations.
Passport Health was founded in 1994 by Fran Lessans. Each travel clinic serves its local community via convenient locations where the public can access travel medicine specialists who have received rigorous training in the fields of travel medicine and immunology.
The CEO and founder of Passport Health, Fran Lessans said;
“We are pleased to be able to offer our travelers a natural over-the-counter product that has been widely used in Australia for many years to reduce the risk of travelers’ diarrhea, the #1 ailment encountered by travelers.”
Immuron CEO Thomas Liquard added;
“We are excited to have the product available throughout such an experienced and wide reaching travel medicine clinic chain such as Passport Health via both their corporate and independent franchises. This is another major agreement for Travelan in the US for 2015, as we continue to grow the Travelan brand in the US through new distribution and retail partners.”
Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, a rich source of antibodies that bind to Enterotoxigenic E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralising their ability to cause Travelers’ Diarrhea and its associated symptoms. Hyperimmune Colostrum is developed under Immuron’s proprietary technology engineered to be high in antibodies targeting a range of E- Coli bacteria that is present in normal colostrum in very small amounts.
Immuron Ltd (ASX:IMC) (OTCQB:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travelers’ diarrhea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.
Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).
Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.
Contact: Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 email@example.com Immuron Investor Relations: Jon Cunningham RedChip Companies, Inc. (407) 644-4256, ext. 107 firstname.lastname@example.org